Compare Garmin Ltd. (GRMN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs TransMedics Group Inc — how do they compare? Garmin Ltd. trades at $247.75 (market cap $46.62B), while TransMedics Group Inc trades at $76.48 (market cap $2.61B). The key difference: Garmin Ltd. is far larger — about 17.9× TransMedics Group Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| GRMN | TMDX | |
|---|---|---|
Market Cap | $46.62B | $2.61B |
Sector | Technology | Technology |
52-Week High | $267.52 | $150.42 |
52-Week Low | $187.10 | $61.99 |
Enterprise Value | $44.09B | $3.01B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $241.39, down 0.91% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 52. The stock shows strong fundamentals with 2025 revenue of $7.25B, net income margin of 23.26%, and consistent earnings beats in recent quarters. Recent product launches in aviation and marine electronics highlight innovation, while cash flow remains positive at $199.21M in 2025.
GRMN presents a solid investment case with robust profitability and growth, though valuation ratios like a P/E of 26.98 suggest premium pricing. Risks include competitive pressures and market volatility, but analyst consensus targets $281.50, indicating ~17% upside. The outlook is positive if earnings momentum continues, supported by dividend stability and institutional confidence.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
